Transcript Yuko - Genomic

Genomic Health, Inc.
Yuko Soneoka, Ph.D., J.D.
Senior Corporate Counsel, IP
Director of Intellectual Property
January 31, 2013
What We Do
• Genomic Health is a global personalized genomics health
company focusing on cancer
• Conduct studies to understand which patterns of gene
expression within a tumor are linked to a response to cancer
therapy or to the likelihood that the cancer will return or
metastasize
• Develop clinically validated tests that provide the genomic
profile of an individual’s tumor in the form of a “score” that
helps individualize cancer treatment planning
2
Leading a Revolution in Cancer Care
Do I need
chemotherapy?
Do I have an
aggressive
disease?
Do I need
radiation?
Do I need
surgery?
Invasive
Breast Cancer
Stage II/ MMR
Colon Cancer
DCIS
Breast Cancer
Prostate
Cancer
2005
2006
2007
2008
2009
2010
NGS Research
3
* Estimated
2011
2012
Do I need
Oxaliplatin?
Stage II/III
Colon Cancer
2013*
NGS Development
2014*
DCIS Breast Cancer Assay
DCIS Score Identifies
75% of Patients with
Lower Risk Disease
Who May Avoid
Radiation Treatment
“One of the year’s leading
medical breakthroughs…”
4
Delivering Better Outcomes in Cancer
Cancer’s Toll in 2012
•1.6 million new cancers will be diagnosed
in the U.S.1
•~577,000 patients will die from their disease1
•80 billion dollars will be spent on cancer
therapies with an average efficacy of 25%2
•60 billion dollars will be wasted
In Early Stage ER+ Invasive
Breast Cancer
•>100,000 patients will be diagnosed in the U.S.
•>50% percent will receive chemotherapy3
•<4% of N- patients will benefit from chemotherapy
The Oncotype DX® Value Proposition
•Demonstrated 37% change in early-stage
breast cancer treatment decisions
•Hundreds of millions of dollars in
healthcare savings
•>320,000 patients tested
5
1 ACS 2012; 2 Burrill 2009; 3 Company estimates
Thank You
6